There are currently 5 active clinical trials seeking participants for Myelodysplastic Syndromes research studies. The states with the highest number of trials for Myelodysplastic Syndromes participants are .
ELEMENT-MDS: A Study to Compare the Efficacy and Safety of Luspatercept in Participants With Myelodysplastic Syndrome (MDS) and Anemia Not Receiving Blood Transfusions
NCT05949684
Recruiting
The purpose of the study is to compare the efficacy and safety of Luspatercept vs epoetin alfa in the treatment of anemia in adults due to IPSS-R very low, low, intermediate-risk MDS in ESA-naïve participants who are non-transfusion dependent (NTD).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/18/2025
Locations: Community Cancer Institute, Clovis, California +168 locations
Conditions: Myelodysplastic Syndromes
Register for Updates
A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
NCT04256317
Recruiting
Study ASTX030-01 is a multi-phase study comprising of Phases 1-3 Monotherapy arms and a Phase 1 Combination Therapy arm Phase 1 Monotherapy consists of an open-label Dose Escalation Stage (Stage A) using multiple cohorts at escalating dose levels of oral cedazuridine and azacitidine (only one study drug will be escalated at a time) followed by a Dose Expansion Stage (Stage B). Phase 2 Monotherapy is a randomized, open-label, crossover study to compare oral ASTX030 to subcutaneous (SC) azacitidin... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/01/2025
Locations: Keck School of Medicine of USC, Los Angeles, California +25 locations
Conditions: Myelodysplastic Syndromes, Acute Myeloid Leukemia, Myelodysplastic Syndrome/Neoplasm, Chronic Myelomonocytic Leukemia
Register for Updates
OURA Ring Wearable Testing in MDS Patients: a Feasibility and Discovery Pilot Study
NCT06270771
Recruiting
A prospective, single center, single arm phase 2 cohort feasibility study of the OURA ring in adult MDS patients. Patients with MDS will wear the OURA ring and upload biometrics weekly. Quality of life measures will be clinically evaluated and correlated with biometrics. We hypothesize that it will be feasible for MDS patients to wear the OURA ring 70% of the time for 3 months.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/02/2025
Locations: Sunnybrook Health Sciences Research Centre, Toronto, Ontario
Conditions: MDS, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, RARS-T
Register for Updates
Evaluation of Tranexamic Acid in Myelodysplastic Syndromes and Acute Myeloid Leukemia
NCT06599762
Recruiting
Myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) are serious, life changing blood cancers. Patients with MDS and AML commonly experience complications related to bleeding, which affect patient quality-of-life and can sometimes lead to hospitalization or death. The investigators will conduct a randomized controlled trial to evaluate the effectiveness and safety of tranexamic acid (TXA; a medication that prevents clots from dissolving) to prevent bleeding. In this study, 50% of pat... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/05/2025
Locations: CancerCare Manitoba, Winnipeg, Manitoba
Conditions: Myelodysplastic Syndromes, Acute Myeloid Leukemia
Register for Updates
Tamibarotene Plus Azacitidine in Participants With Newly Diagnosed RARA-positive Higher-Risk Myelodysplastic Syndrome
NCT04797780
Recruiting
This study compares the efficacy of Tamibarotene in combination with azacitidine to azacitidine in combination with placebo in participants who are Retinoic Acid Receptor Alpha (RARA) positive, and newly diagnosed with higher-risk myelodysplastic syndrome (HR-MDS), and who have not received treatment for this diagnosis. The primary goal of the study is to compare the complete remission rate between the two treatment arms.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/08/2024
Locations: University of Arizona, Tucson, Arizona +136 locations
Conditions: Myelodysplastic Syndromes
Register for Updates